You want your bloodwork to lead to answers, not another stretch of waiting without knowing what happens next. For your Biomarker Audit, ask the clinical team for a turnaround estimate tied to your specific lab order and collection date. The every-90-day testing schedule is not a results-delivery deadline. Also ask when your physician will review the findings, because a completed laboratory report and a treatment decision are different milestones.
- For how long does it take to get biomarker audit results back, request an order-specific estimate from the clinical team.
- GoodLife Health includes a Biomarker Audit every 90 days. That schedule does not describe laboratory turnaround.
- Ask whether your specimen was received, which tests remain pending and when physician review is expected.
- Do not change GLP-1, hormone or thyroid medication based on an isolated laboratory result.
Why this matters
Waiting feels different when you are worried that persistent fatigue, weight changes or an abnormal result will be dismissed again. The fear is a late report and a plan that never considers your systems together. It is spending more time on a treatment plan without understanding whether your metabolic, hormonal and cardiovascular health are being considered together.
Our GoodLife Health Cardiometabolic Optimization model connects those systems through recurring biomarker testing and physician-directed care. The goal is a useful clinical explanation, not simply a collection of numbers. GoodLife Health is best for patients who want recurring biomarker testing connected to ongoing primary care.
In 2026, our membership is $299 per month, with a two-month initial commitment and a $598 first charge. Your membership fee does not rise because your prescription or dose changes. A Biomarker Audit every 90 days is included. Medication is billed separately by the pharmacy at pharmacy cost, with zero markup.
That distinction matters when you are comparing a continuing clinical relationship with a prescription alone. You are paying for care that includes recurring laboratory assessment, not a stronger dose. Our guide to direct primary care for chronic disease management explains the role of that ongoing relationship.
How long does it take to get Biomarker Audit results back?
Use an estimate for your actual order, not a generic blood-test timeline. A Biomarker Audit includes different laboratory measurements and the relevant question is when the findings needed for your clinical assessment will be available and reviewed.
Start by identifying which part of the process you are asking about. Scheduling a draw, having blood collected, completing laboratory testing and receiving a physician's interpretation are not interchangeable events. A useful update names the stage rather than simply saying that your results are coming.
Biomarker Audit milestones
What each stage tells you and what to ask
| Milestone | What it tells you | What to ask |
|---|---|---|
| Blood collection | Your specimen has been collected | What collection date is recorded? |
| Specimen receipt | The laboratory has received the specimen | Has receipt been confirmed? |
| Testing status | Ordered measurements are complete or pending | Which tests remain outstanding? |
| Report completion | The laboratory report is available | Is this the complete order or a partial report? |
| Clinical review | Your physician interprets the findings | What happens next and when? |
For your 2026 care planning, request both the laboratory estimate and the expected review step. Do not schedule a medication change around an assumed delivery date. Your physician needs to decide which findings are necessary before making that decision.
Ask for an estimate with a clear starting point
An estimate is useful only when you know what starts the clock. Ask whether the quoted timing begins with collection or with laboratory receipt and whether it refers to calendar days or business days. Those details prevent two people from discussing different deadlines without realizing it.
Also ask what the estimate covers. The first available result is not necessarily the complete Biomarker Audit. If your immediate concern is a refill or a symptom, tell the clinical team so the question is about your care decision, not just the report's status.
What should you do while you are waiting?
You do not need to interpret a laboratory workflow to request a clear update. Bring the collection date, the reason for testing and the decision you are waiting to make. That gives the clinical team a specific question to resolve.
- Confirm the collection date. Use the date your blood was actually drawn, not the date the order was placed or the appointment was booked.
- Ask whether specimen receipt is confirmed. This separates a collection or transport question from a testing question.
- Request the status of outstanding tests. Ask whether the order is complete, partially complete or awaiting a specimen-related issue to be resolved.
- Clarify the review plan. Ask whether your physician needs the full panel before discussing your particular concern.
- Agree on the next follow-up point. Request a specific date to check back if the expected update does not arrive.
A message can be brief: include your draw date, ask what remains pending and explain whether you are waiting on a treatment decision. Avoid sending only a request for results without identifying the collection. Specific information makes the question easier to answer accurately.


Why laboratory turnaround varies
Laboratory turnaround depends on the work required for the ordered tests and the condition of the specimen. These are general laboratory considerations, not a diagnosis of why your particular report is pending. Ask the clinical team which factor actually applies before assuming there is a delay.
- Specimen receipt. Collection and receipt are separate events. Confirm both before comparing elapsed time with an estimate.
- Test methods. Different biomarkers require different laboratory methods. Do not assume every measurement follows the same processing schedule.
- Specimen suitability. A specimen that does not meet testing requirements can require clarification or another collection. Ask whether any specimen issue has been identified.
- Laboratory verification. Testing sometimes requires repeat analysis or additional checks before a result is finalized. A pending result alone does not identify the reason.
- Clinical review. Your physician's interpretation is a separate step from laboratory analysis. Ask about both rather than treating report completion as the end of care.
Do not read a slow result as evidence that something is wrong. Turnaround time does not tell you whether a result will be normal or abnormal. Only the completed findings, interpreted in clinical context, can answer that question.
Turnaround time does not tell you whether a result will be normal or abnormal. Only the completed findings, interpreted in clinical context, can answer that question.
A completed laboratory report and a treatment decision are different milestones.
What happens between collection and a treatment decision?
Think about the process as four distinct tasks: Collection, Laboratory testing, Clinical review and Care plan. Each answers a different question, from whether a specimen was obtained to whether a treatment change is appropriate. Keeping those tasks separate helps you ask for the update you actually need.

A completed laboratory report and a treatment decision are different milestones.
Clinical review should connect the findings with your symptoms, medication list, medical history and reason for testing. A laboratory reference range is part of that assessment, not a substitute for it. Similarly, a flagged result does not automatically establish a diagnosis or justify a prescription.
Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. Your treating physician determines what the results mean for your care. The laboratory measures biomarkers. The physician makes clinical decisions.
What is included in the Biomarker Audit?
Our 2026 Cardiometabolic Optimization Membership includes a Biomarker Audit every 90 days or 4 audits per year. Testing runs through Quest Diagnostics. The included Cardiometabolic Optimization Panel covers Hs-CRP, Comprehensive Metabolic Panel, TSH With Reflex To Free T4, Fasting Insulin, Lipoprotein (A), Hemoglobin A1c (HbA1c), Lipid Panel, Standard, Apolipoprotein B (ApoB) and CBC (Includes Differential And Platelets).
Those measurements address related parts of the same system. Apolipoprotein B (ApoB) and Lipoprotein (A) inform cardiovascular risk assessment. Hemoglobin A1c (HbA1c) reflects blood sugar exposure over time. Thyroid findings require interpretation alongside symptoms and treatment history. No single marker explains every concern.
This breadth is a reason to ask whether the report is complete before interpreting it yourself. It is not a reason to assume every patient needs every possible intervention. Testing should inform a clinical decision, including the decision that a medication change is not indicated.
Recurring testing provides a framework for follow-up, not a promise that every value needs correction. Your physician should explain which findings matter, which need confirmation and which do not change the plan. More measurements are useful only when they improve the clinical assessment.
Does every 90 days mean I wait 90 days for results?
Every 90 days describes the included Biomarker Audit cadence, not the time required to return results. It tells you how frequently the recurring audit is included in membership. It does not establish a laboratory turnaround guarantee or a deadline for a physician discussion.
Keep these dates separate in your records: your blood collection date, the expected report date supplied for that order and your next planned reassessment. Combining them into a single timeline creates avoidable confusion. Ask the clinical team which date applies to your current question.
Do I have to wait for the entire panel before discussing a concern?
Every 90 days is the routine audit schedule, not an instruction to postpone reporting symptoms. Tell the clinical team about a new concern while testing is pending. Your physician determines whether available information is sufficient or whether additional findings are needed.
Do not decide on your own that a partial report is enough to start or change treatment. The same caution applies in the other direction: do not assume a pending measurement means you must remain silent about worsening symptoms. The clinical question determines the next step.
What if I need testing before the next quarterly audit?
Every 90 days is the included testing cadence. Additional labs beyond that cadence are ordered by the clinician when there is a reason and are billed by the lab at its own rates. Ask your physician whether earlier testing is clinically necessary and clarify the charge before proceeding. A routine schedule does not replace individualized medical judgment.
For example, a new symptom or a treatment-monitoring question deserves clinical assessment rather than an automatic decision to wait for the next audit. That does not mean another blood draw is always necessary. Your physician should explain what question an additional test would answer.
How should you prepare for the results discussion?
Use the waiting period to organize information your physician cannot learn from bloodwork alone. Write down the symptoms that concern you, when they began and whether they changed after a medication adjustment. Include prescription medicines, nonprescription products and supplements.
Record relevant collection circumstances as well. Tell the clinical team if you did not follow the preparation instructions or if you are unsure about them. Do not try to correct the situation by stopping medication or repeating a fast without medical direction.
For a useful discussion, bring these questions:
- Which findings change my care plan and why?
- Does any result need confirmation before we act?
- How do the findings fit with my symptoms and existing diagnoses?
- What should I continue and what should I change?
- What symptoms should prompt contact before the next audit?
- What will we reassess at follow-up?
Ask for the reasoning, not just the recommendation. Understanding why a result matters makes it easier to follow the plan and recognize when something has changed. It also prevents a laboratory flag from becoming a source of unnecessary alarm.
What should you avoid while results are pending?
Do not independently increase, stop or restart GLP-1, hormone or thyroid medication because you are waiting for bloodwork. Contact your treating clinician for instructions. A delayed report is not a dosing recommendation and an isolated result is not a complete treatment plan.
Do not independently increase, stop or restart GLP-1, hormone or thyroid medication because you are waiting for bloodwork. A delayed report is not a dosing recommendation and an isolated result is not a complete treatment plan.
Avoid adding supplements simply to move a number toward a preferred range. Some supplements interfere with laboratory testing and changes made without discussion can complicate interpretation. Give your physician an accurate list rather than assuming nonprescription products are irrelevant.
Urgent symptoms require a different response. Chest pain, severe shortness of breath, fainting or stroke symptoms warrant emergency evaluation rather than waiting for a Biomarker Audit or a routine message response. Laboratory follow-up is not emergency care.
What does membership cover while this care continues?
In 2026, GoodLife Health's Cardiometabolic Optimization Membership combines precision direct primary care with the included quarterly Biomarker Audit. Its structural advantage is continuity: metabolic, hormonal and cardiovascular findings inform one care relationship rather than being treated as unrelated reports.
The financial boundary is equally specific. One flat fee for the doctor. Nothing taken on the medicine. Membership is $299 a month and month to month. $598 is held at sign-up and covers the first two months. It is charged only once the clinician accepts you and if the clinician cannot accept you, the hold is released and you are never charged.
Medication is separate from membership and is billed by the pharmacy at its own price. There is no molecule upcharge or dose-escalation fee from our membership model. That does not mean your pharmacy bill is fixed or that a prescription is guaranteed. Clinical suitability and medication charges remain separate questions.
The trade-off deserves equal clarity. Membership requires an ongoing payment, the first two months are charged and non-refundable once you are accepted and additional testing beyond the included cadence is billed by the lab at its own rates. It also does not establish a guaranteed laboratory completion date. The value is recurring assessment connected to care, not a promise of instant results.
If that is the relationship you want, review the membership terms and decide whether the commitment fits your needs. Ask about the testing and review process before joining, especially if a pending treatment decision makes timing important to you.
FAQ
How long does it take to get Biomarker Audit results back?
Ask the clinical team for an estimate tied to your specific order and collection date. Confirm whether that estimate covers the complete laboratory report, physician review or both.
Does the every-90-day Biomarker Audit schedule mean results take 90 days?
No. Every 90 days describes the included recurring testing schedule, not laboratory turnaround or the time until physician review.
Can different parts of my bloodwork be completed at different times?
Different laboratory measurements can have different processing schedules. Ask whether your report is complete and which ordered tests remain pending before treating available findings as the full assessment.
Does a pending result mean something is wrong?
A pending result does not establish that a finding is abnormal. Ask the clinical team about the actual testing status rather than using elapsed time to interpret your health.
Should I change my medication while I wait for results?
Do not independently change GLP-1, hormone or thyroid medication while waiting for results. Ask your treating clinician for instructions, especially if you have new symptoms or a refill question.
Who delivers clinical care through the membership?
Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. Your treating physician interprets the findings and determines your care plan.
Are additional labs included between quarterly Biomarker Audits?
Additional labs beyond the included every-90-day cadence are billed at pass-through cost. Ask your physician whether the testing is necessary and clarify the charge before proceeding.
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/